NET/EE

Phase 1Small molecule

Vertex Pharmaceuticals

NET/EE is one of 35 small molecule programs targeting Oral. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseaseNot yet recruiting

OralPhase 1

Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

50 competitors in Oral

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Marinol

Jazz Pharmaceuticals

Phase 1

2 3

GTX-104

GGrace Therapeutics Inc.

Phase 3

1 4

SHR-3167

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 5

Nubain

AAultman Health Foundation

Preclinical

1 6

Pitressin

AAultman Health Foundation

Preclinical

1 7

DRSP/EE

Vertex Pharmaceuticals

Phase 1

1 8

VX-407

Vertex Pharmaceuticals

Phase 1

1 9

AB-101

AArtiva Biotherapeutics, Inc.

Phase 1

1 10

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Autosomal Dominant Polycystic Kidney Disease

NCT07792408

Clinical

Trials by Indication[1]

Oral1 trial

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07074327·74 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Not yet recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07792408·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NET/EE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NET/EE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NET/EE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Vertex Pharmaceuticals

NET/EE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Oral1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News